Drug Trial Radar · NCT07345442
Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 14, 2025
Primary completion
Jun 9, 2025
Study completion Jun 9, 2025
Sponsor
- Lead sponsor
- Anhui Palo Alto Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult
Conditions
- Allergic Rhinitis
Interventions
PA9159 nasal spray solution, 80 μg one day treatmentDrug
Single dose of PA9159 (20 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.nostril.
PA9159 nasal spray solution, 160 μg one day treatmentDrug
Single dose of PA9159 (40 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
PA9159 nasal spray solution, 320 μg one day treatmentDrug
Single dose of PA9159 (80 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
PA9159 nasal spray solution, 80 μg 7-day treatmentDrug
Repeated doses of PA9159 (20 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
PA9159 nasal spray solution, 160 μg 7-day treatmentDrug
Repeated doses of PA9159 (40 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
PA9159 nasal spray solution, 320 μg 7-day treatmentDrug
Repeated doses of PA9159 (80 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Placebo, the same intranasal spray solution without PA9159 active ingredientDrug
Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects experiencing adverse events (AEs)Time frame: up to 7 days after last nasal spray treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.